Commonly used to mitigate inflammation caused by illnesses, the corticosteroid class, known as glucocorticoids, has been reported to induce a negative impact that may restrict its utility. Reducing the severity of glucocorticoid action may allow for greater quantities of research compounds and longer application durations. Multiple studies have suggested that Ipamorelin may mitigate and sometimes reverse the impact of glucocorticoid applications.
Ipamorelin Peptide and Bones
Loss of bone density and increased fracture risk are major issues with long-term glucocorticoid usage. Bisphosphonates, hormone manipulation, and novel monoclonal antibodies are available. Although each application has been reported to be moderately successful, they may have undesirable consequences, limited use, or exorbitant price tags. Rat studies suggest that Ipamorelin may mitigate bone loss associated with corticosteroids and even improve bone growth by a factor of four [i]. As research suggests, the strength of preexisting and freshly created bone may be increased if Ipamorelin exerts the potential to enhance bone mineral density systemically.
Ipamorelin Peptide and Muscle
Some research suggests that glucocorticoids’ muscle-wasting action may be mitigated by GH or a growth hormone secretagogue such as Ipamorelin. Recent studies suggest that Ipamorelin may improve nitrogen balance and reduce nitrogen loss in the liver of glucocorticoid rats [ii]. Subjects undergoing glucocorticoid research may be aided by a compound that might prevent muscle catabolism and bone density loss.
Ipamorelin Peptide and Diabetes
In studies with diabetic rats, Ipamorelin has been hypothesized to increase insulin secretion. Insulin-producing and—storing pancreatic islet cells presumably undergo indirect calcium channel activation, accounting for this action [iii]. Understanding how Ipamorelin may affect the pancreas might pave the way for new prevention strategies for diabetes research.
Ipamorelin Peptide and POI
Post-operative ileus (POI) often occurs after surgery and is most prevalent after abdominal surgery. Although pain is a symptom of POI, its greatest drawback is the time it adds to a subject’s recovery and rehabilitation.
Several proof-of-concept clinical studies have examined the peptide Ipamorelin to see whether it may be used to lessen POI. Studies suggest that Ipamorelin may reduce the time before the first meal by around 12 hours. Despite some initial success, the business running the trials judged that the results weren’t promising enough to warrant further development. Ongoing studies may provide results that increase the impact, or studies of combinations that contain Ipamorelin may identify a synergistic combination with other substances that may increase the efficacy, research suggests.
The Lack of Study on Ipamorelin
Even though Ipamorelin is not an orphan compound, it is under-researched in clinical settings. The decision not to pursue Ipamorelin for post-operative ileus dampened enthusiasm for the peptide, which had suggested potential in preliminary investigations. In addition to its research potential, studies suggest Ipamorelin may be used to gain insight into the physiologic action of various disease situations.
More investigation is required to explore its potential in scientific research, and these studies must continue. Only academic and scientific institutions are allowed to use Ipamorelin peptides. If you are a licensed professional interested in finding peptides for sale for your clinical studies, visit Biotech Peptides. Please note that none of the items mentioned are approved for human or animal consumption. Laboratory research chemicals are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. Only authorized academics and working professionals may make purchases. The content of this article is intended only for instructional purposes.
References
[i] N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
[ii] N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009. [PubMed]
[iii] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
[iv] M. M. Fowkes, T. Lalonde, L. Yu, S. Dhanvantari, M. S. Kovacs, and L. G. Luyt, “Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor,” Eur. J. Med. Chem., vol. 157, pp. 1500–1511, Sep. 2018. [Science Direct]